• New QIAsprint Connect system can process up to 192 samples per run.
• Company will also present QIAsymphony Connect for clinical labs and the QIAmini system for low-throughput needs.
• The public showcase is scheduled for February 9 at the SLAS 2026 conference in Boston.
BOSTON, United States – A new suite of laboratory automation tools is set for its public debut. QIAGEN announced on February 3, 2026, that it will showcase its new QIAsprint Connect high-throughput automation system at the SLAS 2026 conference, marking the company’s entry into this segment of the sample processing market.
The system is designed for research laboratories seeking to increase sample processing capacity while managing flexibility and sustainability.
This story was produced by our AI-assisted newsroom. Learn more about our verification process.
What is new?
QIAGEN is holding the first public showcase of its QIAsprint Connect system at the SLAS 2026 conference in Boston. The announcement marks the company’s move into high-throughput benchtop automation for research laboratories. According to the company, the new platform is engineered to help labs process large quantities of samples efficiently while reducing their environmental footprint. The live unveiling is scheduled for February 9 at 2:30 p.m. EST.
Key Details of QIAsprint Connect
The QIAsprint Connect system is designed to process up to 192 samples in a single run with minimal manual intervention. It features a compact benchtop footprint to fit into existing laboratory spaces. The platform offers customizable workflows through a touch-based interface and modular kit design. It also supports modern data integrity and cybersecurity requirements, including 21 CFR Part 11 readiness for compliance.
A key feature highlighted by the company is its sustainability-focused consumables. The new kits are designed to reduce plastic use by up to 50% and packaging volume by 40% compared to previous solutions, without compromising performance.
Expanding the Automation Portfolio
In addition to QIAsprint Connect, QIAGEN will present two other automation systems at the event. The QIAsymphony Connect is the next generation of its automated platform for high-yield DNA and RNA isolation in clinical applications, featuring complete sample tracking. For smaller facilities, the company is introducing the QIAmini, a compact benchtop solution that provides walkaway sample preparation for lower-throughput laboratories.
“QIAsprint Connect is designed to help labs meet those demands and reflects QIAGEN’s strategy to expand automation across all throughput needs,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. He noted that the new systems strengthen the company’s offerings at the critical starting point of laboratory workflows.
About this company
QIAGEN N.V. is a Netherlands-based holding company that provides Sample to Insight solutions for customers to extract and analyze molecular information from biological samples. Its technologies isolate and process DNA, RNA, and proteins from materials such as blood and tissue. The company’s automation solutions are designed to integrate these steps into streamlined workflows.
QIAGEN serves more than 500,000 customers globally in the Life Sciences and Molecular Diagnostics sectors, which include academia, pharmaceutical research, and clinical healthcare. As of December 31, 2025, the company employed approximately 5,700 people across more than 35 locations worldwide.
Read more
Update: Swiss RE Sees Large Financing Gap In Flood Prevention
Update: Berlin Leads in Heat Pump Adoption Among Major German Cities